Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC

Nishio M.Felip E.Orlov S.Park K.CHONG-JEN YUTsai C.-M.Cobo M.McKeage M.Su W.-C.Mok T.Scagliotti G.V.Spigel D.R.Viraswami-Appanna K.Chen Z.Passos V.Q.Shaw A.T.2022-06-272022-06-2720201556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078128722&doi=10.1016%2fj.jtho.2019.11.006&partnerID=40&md5=5931a27ee6ecc1c7450e67438c68bfe2https://scholars.lib.ntu.edu.tw/handle/123456789/614025[SDGs]SDG3Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLCconference paper10.1016/j.jtho.2019.11.006317787982-s2.0-85078128722